GOSS insider transaction filings

Gossamer Bio, Inc. — 37 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-05. Screen GOSS transaction legs live →

FiledFormInsiderReported transactionsSource
2026-06-054Nathan Steven D — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2026-06-054Drynan Skye — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2026-06-054Milligan Sandra — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2026-06-054Quisel John D — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2026-06-054Daniel Thomas O — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2026-06-054Cox Russell J. — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2026-03-204Smith Robert Paul JR — Chief Commercial OfficerDisposition to issuer (D): 562,500 (derivative) · Disposition to issuer (D): 572,000 (derivative) · Grant/award (A): 562,500 (derivative) · Grant/award (A): 572,000 (derivative)EDGAR
2026-03-204Aranda Richard — Chief Medical OfficerDisposition to issuer (D): 562,500 (derivative) · Disposition to issuer (D): 572,000 (derivative) · Disposition to issuer (D): 487,500 (derivative) · Disposition to issuer (D): 162,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · +18 moreEDGAR
2026-03-204Peterson Caryn — EVP, Regulatory AffairsDisposition to issuer (D): 506,250 (derivative) · Disposition to issuer (D): 440,000 (derivative) · Disposition to issuer (D): 375,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 157,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · +18 moreEDGAR
2026-03-204Giraudo Bryan — COO/CFODisposition to issuer (D): 693,750 (derivative) · Disposition to issuer (D): 638,000 (derivative) · Disposition to issuer (D): 543,750 (derivative) · Disposition to issuer (D): 181,250 (derivative) · Disposition to issuer (D): 211,500 (derivative) · Disposition to issuer (D): 211,500 (derivative) · +16 moreEDGAR
2026-03-204Christian Waage — EVP, Tech Ops and AdminDisposition to issuer (D): 506,250 (derivative) · Disposition to issuer (D): 440,000 (derivative) · Disposition to issuer (D): 375,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 157,500 (derivative) · Disposition to issuer (D): 157,500 (derivative) · +14 moreEDGAR
2026-03-204Hasnain Faheem — President & CEO, DirectorDisposition to issuer (D): 1,680,000 (derivative) · Disposition to issuer (D): 1,540,000 (derivative) · Disposition to issuer (D): 1,312,500 (derivative) · Disposition to issuer (D): 437,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · +14 moreEDGAR
2026-01-054Smith Robert Paul JR — Chief Commercial OfficerGrant/award (A): 93,750 @ $0 · Grant/award (A): 562,500 (derivative) @ $0EDGAR
2026-01-054Aranda Richard — Chief Medical OfficerGrant/award (A): 93,750 @ $0 · Grant/award (A): 562,500 (derivative) @ $0EDGAR
2026-01-054Peterson Caryn — EVP, Regulatory AffairsGrant/award (A): 84,500 @ $0 · Grant/award (A): 506,250 (derivative) @ $0EDGAR
2026-01-054Giraudo Bryan — COO/CFOGrant/award (A): 115,750 @ $0 · Grant/award (A): 693,750 (derivative) @ $0EDGAR
2026-01-054Christian Waage — EVP, Tech Ops and AdminGrant/award (A): 84,500 @ $0 · Grant/award (A): 506,250 (derivative) @ $0EDGAR
2026-01-054Hasnain Faheem — President & CEO, DirectorGrant/award (A): 280,000 @ $0 · Grant/award (A): 1,680,000 (derivative) @ $0EDGAR
2025-10-024Smith Robert Paul JR — Chief Commercial OfficerGrant/award (A): 162,500 @ $0EDGAR
2025-10-024Aranda Richard — Chief Medical OfficerGrant/award (A): 162,500 @ $0EDGAR
2025-10-024Peterson Caryn — EVP, Regulatory AffairsGrant/award (A): 125,000 @ $0EDGAR
2025-10-024Giraudo Bryan — COO/CFOGrant/award (A): 181,250 @ $0EDGAR
2025-10-024Christian Waage — EVP, Tech Ops and AdminGrant/award (A): 125,000 @ $0EDGAR
2025-10-024Hasnain Faheem — President & CEO, DirectorGrant/award (A): 437,500 @ $0EDGAR
2025-08-204Milligan Sandra — DirectorPurchase (P): 26,050 @ $1.92EDGAR
2025-06-264Nathan Steven D — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2025-06-264Milligan Sandra — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2025-06-264Drynan Skye — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2025-06-264Quisel John D — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2025-06-264Daniel Thomas O — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2025-06-264Cox Russell J. — DirectorGrant/award (A): 115,000 (derivative) @ $0EDGAR
2025-03-064Peterson Caryn — EVP, Regulatory AffairsGrant/award (A): 440,000 (derivative) @ $0EDGAR
2025-03-064Smith Robert Paul JR — Chief Commercial OfficerGrant/award (A): 572,000 (derivative) @ $0EDGAR
2025-03-064Aranda Richard — Chief Medical OfficerGrant/award (A): 572,000 (derivative) @ $0EDGAR
2025-03-064Giraudo Bryan — COO/CFOGrant/award (A): 638,000 (derivative) @ $0EDGAR
2025-03-064Christian Waage — EVP, Tech Ops and AdminGrant/award (A): 440,000 (derivative) @ $0EDGAR
2025-03-064Hasnain Faheem — President & CEO, DirectorGrant/award (A): 1,540,000 (derivative) @ $0EDGAR

Recent 8-K events — Gossamer Bio, Inc.

FiledFormItems reportedSource
2026-08-218-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-278-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-158-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-018-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-178-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-058-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-058-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-06-028-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-188-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
8.01 — Other Events
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GOSS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →